Last quarter (Q4 2022), Oxford BioDynamics's total revenue was £―, a decrease of ― from the same quarter last year. In Q4, Oxford BioDynamics's net income was £―. See Oxford BioDynamics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Sep 23	Sep 22	Sep 21	Sep 20	Sep 19
Total Revenue	-	£ 510.00K	£ 154.00K	£ 341.00K	£ 456.00K	£ 907.00K
Cost of Revenue	-	£ 244.00K	£ 38.00K	-	£ 622.00K	£ 468.00K
Gross Profit	-	£ 266.00K	£ 116.00K	£ 341.00K	£ -166.00K	£ 439.00K
Operating Expense	-	£ 10.10M	£ 8.32M	£ 7.60M	£ 4.79M	£ 4.16M
Operating Income	-	£ -9.84M	£ -8.21M	£ -251.00K	£ -4.95M	£ -3.72M
Net Non Operating Interest Income Expense	-	£ -141.00K	£ -184.00K	£ -83.00K	£ 102.00K	£ 196.00K
Other Income Expense	-	£ 1.58M	£ -701.00K	£ 34.00K	-	-
Pretax Income	-	£ -11.41M	£ -7.57M	£ -7.63M	£ -4.95M	£ -3.39M
Tax Provision	-	£ -585.00K	£ -857.00K	£ -947.00K	£ -597.00K	£ -586.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	£ -10.83M	£ -6.71M	-	£ -4.35M	£ -2.80M
Basic EPS	-	£ -0.08	£ -0.07	-	£ -0.05	£ -0.03
Diluted EPS	-	£ -0.08	£ -0.07	-	£ -0.05	£ -0.03
Basic Average Shares	-	£ 147.48M	£ 99.70M	£ 92.56M	£ 92.56M	£ 92.56M
Diluted Average Shares	-	£ 147.48M	£ 99.70M	£ 92.56M	£ 92.56M	£ 92.56M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	£ 38.00K	£ 159.00K
Total Expenses	-	£ 10.35M	£ 8.36M	-	£ 5.41M	£ 4.63M
Net Income From Continuing And Discontinued Operation	-	£ -10.83M	£ -6.71M	£ -6.68M	£ -4.35M	£ -2.80M
Normalized Income	-	£ -12.00M	£ -8.42M	£ -8.58M	£ -4.35M	£ -2.80M
Interest Expense	-	-	-	-	£ 19.00K	£ 0.00
EBIT	-	£ -11.20M	£ -7.37M	£ -7.71M	£ -4.93M	£ -3.39M
EBITDA	-	£ -9.84M	£ -6.16M	£ -6.43M	£ -4.46M	£ -3.00M

Currency in GBP

Oxford BioDynamics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing